In silico predicted adenoviral epitopes elicit a VST response by intracellular flow cytometry. (B) Representative example of a product that had been given to a patient with a complete clinical response. This product has a response to peptides predicted to be presented by DRB1*07:01 but not to the peptide predicted to be presented by DRB1*15:01. (C) Quantitation of the number of adenoviral T cells by ELISpot in 2 recipients of third-party VSTs. PBMCs were stimulated with either adenoviral Pepmix or single peptides with the HLA predicted to present the epitope indicated in the table. At all timepoints, the background media spot counts have been subtracted.